Lifespan of effector memory CD4+ T cells determined by replication-incompetent integrated HIV-1 provirus

AIDS

Volumn 28, Issue 8, 2014, Pages 1091-1099

  Imamichi, Hiromi ^a   Natarajan, Ven ^b   Adelsberger, Joseph W ^b   Rehm, Catherine A ^a   Lempicki, Richard A ^b   Das, Biswajit ^b   Hazen, Allison ^b   Imamichi, Tomozumi ^b   Lane, H Clifford ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b Dept of Applied and Development Research ^*  (United States)

Author keywords

Genetic marker; HIV 1; In vivo persistence of CD4 positive T lymphocytes; Integration; Provirus; Replication incompetent

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; SURAMIN; VIRUS RNA; VIRUS DNA;

ADULT; ARTICLE; BLOOD ANALYSIS; CASE REPORT; CD4+ T LYMPHOCYTE; CELL CLONE; CELL FATE; CELL SEPARATION; CELL SURVIVAL; DNA INTEGRATION; EFFECTOR CELL; GENE MUTATION; HALF LIFE TIME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; INVERSE POLYMERASE CHAIN REACTION; MALE; MEMORY T LYMPHOCYTE; MIDDLE AGED; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROVIRUS; REVERTANT; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS; STOP CODON; T LYMPHOCYTE LIFE SPAN; T LYMPHOCYTE SUBPOPULATION; VIRUS REPLICATION; BLOOD; DNA REPLICATION; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; PATHOGENICITY; POLYMERASE CHAIN REACTION;

CD4-POSITIVE T-LYMPHOCYTES; DNA REPLICATION; DNA, VIRAL; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; POLYMERASE CHAIN REACTION; PROVIRUSES; RNA, VIRAL; VIRUS REPLICATION;

EID: 84925515846     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000223     Document Type: Article

References (38)

1. Sprent J. T and B memory cells. Cell 1994; 76:315-322.
2. Crotty S, Ahmed R. Immunological memory in humans. Semin Immunol 2004; 16:197-203.
3. Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science 1996; 272: 54-60.
4. Sanders ME, Makgoba MW, Shaw S. Human naive and memory T cells: reinterpretation of helper-inducer and suppressorinducer subsets. Immunol Today 1988; 9:195-199.
5. Mackay CR. Immunological memory. Adv Immunol 1993; 53:217-265.
6. Tough DF, Sprent J. Life span of naive and memory T cells. Stem Cells 1995; 13:242-249.
7. Michie CA, McLean A, Alcock C, Beverley PC. Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature 1992; 360:264-265.
8. Neese RA, Misell LM, Turner S, Chu A, Kim J, Cesar D, et al. Measurement in vivo of proliferation rates of slow turnover cells by 2H2O labeling of the deoxyribose moiety of DNA. Proc Natl Acad Sci U S A 2002; 99:15345-15350.
9. McCune JM, Hanley MB, Cesar D, Halvorsen R, Hoh R, Schmidt D, et al. Factors influencing T-cell turnover in HIV-1-seropositive patients. J Clin Invest 2000; 105:R1-R8.
10. Macallan DC, Asquith B, Irvine AJ, Wallace DL, Worth A, Ghattas H, et al. Measurement and modeling of human T cell kinetics. Eur J Immunol 2003; 33:2316-2326.
11. Macallan DC, Wallace D, Zhang Y, De-Lara C, Worth AT, Ghattas H, et al. Rapid turnover of effector-memory CD4(R) T cells in healthy humans. J Exp Med 2004; 200:255-260.
12. Srinivasula S, Lempicki RA, Adelsberger JW, Huang CY, Roark J, Lee PI, et al. Differential effects of HIV viral load and CD4 count on proliferation of naive and memory CD4 and CD8 T lymphocytes. Blood 2011; 118:262-270.
13. Lanzavecchia A, Sallusto F. Dynamics of T lymphocyte responses: Intermediates, effectors, and memory cells. Science 2000; 290:92-97.
14. Bell EB, Westermann J. CD4 memory T cells on trial: Immunological memory without a memory T cell. Trends Immunol 2008; 29:405-411.
15. Sprent J. Lifespans of naive, memory and effector lymphocytes. Curr Opin Immunol 1993; 5:433-438.
16. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004; 22:745-763.
17. Robertson JM, MacLeod M, Marsden VS, Kappler JW, Marrack P. Not all CD4R memory T cells are long lived. Immunol Rev 2006; 211:49-57.
18. Hellerstein MK, Hoh RA, Hanley MB, Cesar D, Lee D, Neese RA, et al. Subpopulations of long-lived and short-lived T cells in advanced HIV-1 infection. J Clin Invest 2003; 112:956-966.
19. Han Y, Lassen K, Monie D, Sedaghat AR, Shimoji S, Liu X, et al. Resting CD4R T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol 2004; 78:6122-6133.
20. Bastie-Sigeac F, Lucotte G. Optimal use of restriction enzymes in the analysis of human DNA polymorphism. Hum Genet 1983; 63:162-165.
21. Imamichi H, Crandall KA, Natarajan V, Jiang MK, Dewar RL, Berg S, et al. Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy. J Infect Dis 2001; 183:36-50.
22. Vartanian JP, Meyerhans A, Sala M, Wain-Hobson S. G->A hypermutation of the human immunodeficiency virus type 1 genome: evidence for dCTP pool imbalance during reverse transcription. Proc Natl Acad Sci U S A 1994; 91:3092-3096.
23. Rose PP, Korber BT. Detecting hypermutations in viral sequences with an emphasis on G -> A hypermutation. Bioinformatics 2000; 16:400-401.
24. Imamichi T, Berg SC, Imamichi H, Lopez JC, Metcalf JA, Falloon J, et al. Relative replication fitness of a high-level 30-azido-30- deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr->Gly) at codon 69. J Virol 2000; 74:10958-10964.
25. Brann TW, Dewar RL, Jiang MK, Shah A, Nagashima K, Metcalf JA, et al. Functional correlation between a novel amino acid insertion at codon 19 in the protease of human immunodeficiency virus type 1 and polymorphism in the p1/p6 Gag cleavage site in drug resistance and replication fitness. J Virol 2006; 80:6136-6145.
26. Gonda MA, Aaronson SA, Ellmore N, Zeve VH, Nagashima K. Ultrastructural studies of surface features of human normal and tumor cells in tissue culture by scanning and transmission electron microscopy. J Natl Cancer Inst 1976; 56:245-263.
27. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418:646-650.
28. Lecossier D, Bouchonnet F, Clavel F, Hance AJ. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 2003; 300:1112.
29. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, et al. DNA deamination mediates innate immunity to retroviral infection. Cell 2003; 113:803-809.
30. Janini M, Rogers M, Birx DR, McCutchan FE. Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during nearsimultaneous infection and activation of CD4(R) T cells. J Virol 2001; 75:7973-7986.
31. Kieffer TL, Kwon P, Nettles RE, Han Y, Ray SC, Siliciano RF. G->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4R T cells in vivo. J Virol 2005; 79:1975-1980.
32. Piantadosi A, Humes D, Chohan B, McClelland RS, Overbaugh J. Analysis of the percentage of human immunodeficiency virus type 1 sequences that are hypermutated and markers of disease progression in a longitudinal cohort, including one individual with a partially defective Vif. J Virol 2009; 83:7805-7814.
33. Fourati S, Lambert-Niclot S, Soulie C, Malet I, Valantin MA, Descours B, et al. HIV-1 genome is often defective in PBMCs and rectal tissues after long-term HAART as a result of APOBEC3 editing and correlates with the size of reservoirs. J Antimicrob Chemother 2012; 67:2323-2326.
34. Land AM, Ball TB, Luo M, Pilon R, SandstromP, Embree JE, et al. Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. J Virol 2008; 82:8172-8182.
35. Gandhi SK, Siliciano JD, Bailey JR, Siliciano RF, Blankson JN. Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J Virol 2008; 82:3125-3130.
36. Eyzaguirre LM, Charurat M, Redfield RR, Blattner WA, Carr JK, Sajadi MM. Elevated hypermutation levels in HIV-1 natural viral suppressors. Virology 2013; 443:306-312.
37. Sester M, Sester U, Gartner BC, Girndt M, Meyerhans A, Kohler H. Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection. J Am Soc Nephrol 2002; 13:2577- 2584.
38. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013; 155:540-551.